Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Class III antiarrhythmic drugs

B N Singh1, R Ahmed

  • 1Section of Cardiology, Veterans Administration Medical Center, West Los Angeles, CA 90073.

Current Opinion in Cardiology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanistic and recent updates in nano-bioremediation for developing green technology to alleviate agricultural contaminants.

International journal of environmental science and technology : IJEST·2022
Same author

A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys.

Computers in biology and medicine·2022
Same author

How is Biodegradable Scaffold Effective in Gap Non-union? Insights from an Experiment.

Indian journal of orthopaedics·2021
Same author

Computational exploration and anti-mycobacterial activity of potential inhibitors of <i>Mycobacterium tuberculosis</i> acetyl coenzyme A carboxylase as anti-tubercular agents.

SAR and QSAR in environmental research·2021
Same author

Fabrication and evaluation of non-mulberry silk fibroin fiber reinforced chitosan based porous composite scaffold for cartilage tissue engineering.

Tissue & cell·2018
Same author

Studies on effect of CuO addition on mechanical properties and in vitro cytocompatibility in 1393 bioactive glass scaffold.

Materials science & engineering. C, Materials for biological applications·2018

The shift towards Class III antiarrhythmic drugs and beta-blockers is driven by concerns about Class I drugs affecting mortality in heart disease patients. Newer agents and implantable devices are being studied for their effectiveness in reducing sudden cardiac death.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Devices

Background:

  • Cardiac arrhythmia treatment is evolving, moving from Class I drugs to Class III agents and beta-blockers.
  • Concerns exist regarding the adverse effects of Class I antiarrhythmic drugs on mortality in patients with structural heart disease.
  • Complex molecules like amiodarone, sotalol, and newer Class III agents are the current focus.

Purpose of the Study:

  • To evaluate the evolving landscape of antiarrhythmic drug therapy.
  • To highlight the shift in clinical trial endpoints towards mortality.
  • To discuss the role of implantable devices in studying antiarrhythmic therapies.

Main Methods:

  • Review of current trends in pharmacological therapy for cardiac arrhythmias.

Related Experiment Videos

  • Analysis of the shift from surrogate endpoints to mortality as the primary endpoint in clinical trials.
  • Exploration of the use of implantable cardioverter-defibrillators in clinical trials.

    • Main Results:

    • Class III agents and beta-blockers are increasingly preferred over Class I drugs due to safety concerns.
    • Implantable devices facilitate mortality-based clinical trials for ventricular arrhythmias.
    • Trials comparing implantable cardioverter-defibrillators with medical therapy are ongoing.

    Conclusions:

    • Newer Class III agents and implantable devices represent a significant advancement in managing cardiac arrhythmias.
    • The optimal antifibrillatory agent that reduces mortality in structural heart disease remains an active area of research.
    • The use of implantable devices is transforming the design and execution of clinical trials for life-threatening arrhythmias.